Verduin Lindsey, Mentrikoski Mark J, Heitz Christopher T, Wick Mark R
Department of Pathology, University of Virginia Health System, Charlottesville, VA.
Appl Immunohistochem Mol Morphol. 2016 Aug;24(7):509-13. doi: 10.1097/PAI.0000000000000221.
The transcription factor GATA3 is a recently described biomarker that is highly expressed in bladder and breast carcinomas. Although it has shown sensitivity as a marker of primary bladder carcinomas with purely urothelial differentiation, the ability of GATA3 to label primary bladder carcinomas with variant morphologic patterns has been incompletely assessed to date. The current study was designed to determine whether GATA3 staining is retained in "unconventional" bladder carcinomas. Eighty-eight cases of primary bladder cancers were retrieved from the authors' institutional archive, and they included the following histomorphologic types: 6 small cell carcinomas, 12 sarcomatoid carcinomas, 17 adenocarcinomas (both primary and urothelial variants with glandular differentiation), 24 micropapillary carcinomas, and 27 squamous cell carcinomas (both primary and urothelial variants with squamous differentiation). A tissue microarray was constructed and automated immunostaining for GATA3 (Clone L50-823, Biocare Medical, Concord, CA) was performed using standard technique. Among the 5 variants of unconventional bladder carcinoma, only the micropapillary and sarcomatoid forms exhibited consistent and strong immunolabeling for GATA3. Hence, the sensitivity of this determinant is diminished in several histologic forms of primary bladder carcinoma. That fact will affect the interpretation of GATA3 stains in the context of possible metastasis from primary bladder carcinomas with variant morphologic patterns, as well as their distinction from secondary bladder involvement by tumors of nonurothelial origin.
转录因子GATA3是一种最近被描述的生物标志物，在膀胱癌和乳腺癌中高度表达。尽管它已显示出作为具有纯尿路上皮分化的原发性膀胱癌标志物的敏感性，但GATA3标记具有变异形态模式的原发性膀胱癌的能力迄今尚未得到充分评估。本研究旨在确定GATA3染色在“非传统”膀胱癌中是否保留。从作者的机构档案中检索了88例原发性膀胱癌病例，它们包括以下组织形态学类型：6例小细胞癌、12例肉瘤样癌、17例腺癌（原发性和具有腺性分化的尿路上皮变异型）、24例微乳头癌和27例鳞状细胞癌（原发性和具有鳞状分化的尿路上皮变异型）。构建了组织芯片，并使用标准技术对GATA3（克隆L50-823，Biocare Medical，康科德，加利福尼亚州）进行自动免疫染色。在非传统膀胱癌的5种变异型中，只有微乳头和肉瘤样形式对GATA3表现出一致且强烈的免疫标记。因此，在原发性膀胱癌的几种组织学形式中，该决定因素的敏感性降低。这一事实将影响在具有变异形态模式的原发性膀胱癌可能转移的情况下对GATA3染色的解读，以及它们与非尿路上皮起源肿瘤引起的继发性膀胱受累的区分。
